Evidence map›Paper›PMID 28388540›Full record

ArticleOncotarget2017

Transcriptional regulation of mixed lineage kinase 3 by estrogen and its implication in ER-positive breast cancer pathogenesis.

Navin Viswakarma, Rakesh Sathish Nair, Gautam Sondarva, Subhasis Das, Lucas Ibrahimi, Zhiyong Chen, Subhash Sinha, Basabi Rana, Ajay Rana

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. CAP superfamily proteins in human: a new target for cancer therapy.Medical oncology (Northwood, London, England) · 2024
    Review
  2. Review
  3. Berberine RepressesMolecular pharmacology · 2021
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Navin ViswakarmaDepartment of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, Chicago, IL 60612, USA.
Rakesh Sathish NairDepartment of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, Chicago, IL 60612, USA.
Gautam SondarvaDepartment of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, Chicago, IL 60612, USA.
Subhasis DasDepartment of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, Chicago, IL 60612, USA.
Lucas IbrahimiDepartment of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, Chicago, IL 60612, USA.
Zhiyong ChenDepartment of Cell and Molecular Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Subhash SinhaDepartment of Cell and Molecular Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Basabi RanaDepartment of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, Chicago, IL 60612, USA.
Ajay RanaDepartment of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, Chicago, IL 60612, USA.
University of Illinois Chicago · USScripps Research Institute · USJesse Brown VA Medical Center · US

Funding

Oncogenic MLK3-Pak1 Signaling in ER Negative Breast CancerR01CA176846 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI RANA, AJAY NMN · 2013 to 2017
$1.6M
Role of beta-catenin in apoptosis resistance of hepatocellular carcinomaR01CA178063 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI RANA, BASABI · 2014 to 2018
$1.6M
Role of Sprouty 2 in Hepatocellular CarcinomaI01BX002355 · VA · JESSE BROWN VA MEDICAL CENTER · PI RANA, AJAY NMN · 2014 to 2017
–
Targeting Mixed Lineage Kinase3-Hedgehog Axis in Pancreatic CancerI01BX002703 · VA · JESSE BROWN VA MEDICAL CENTER · PI RANA, AJAY NMN · 2015 to 2019
–
Elucidation of MLK3 Signaling in Hepatocellular CarcinomaI01BX003296 · VA · JESSE BROWN VA MEDICAL CENTER · PI RANA, BASABI · 2016 to 2022
–
BLRD VA I01 BX002355BLRD VA I01 BX002703BLRD VA I01 BX003296NCI NIH HHS R01 CA176846NCI NIH HHS R01 CA178063
6 · The paper itself

Abstract

Mixed Lineage Kinase 3 (MLK3), also called as MAP3K11 is a tightly regulated MAP3K member but its cellular function is still not fully understood. Earlier we reported post-translational regulation of MLK3 by estrogen (E2) that inhibited the kinase activity and favored survival of ER+ breast cancer cells. Here we report that MLK3 is also transcriptionally downregulated by E2 in ER+ breast cancer cells. Publicly available data and in situ hybridization of human breast tumors showed significant down regulation of MLK3 transcripts in ER+ tumors. The basal level of MLK3 transcripts and protein in ER+ breast cancer cell lines were significantly lower, and the protein expression was further down regulated by E2 in a time-dependent manner. Analysis of the promoter of MLK3 revealed two ERE sites which were regulated by E2 in ER+ but not in ER- breast cancer cell lines. Both ERα and ERβ were able to bind to MLK3 promoter and recruit nuclear receptor co-repressors (NCoR, SMRT and LCoR), leading to down-regulation of MLK3 transcripts. Collectively these results suggest that recruitment of nuclear receptor co-repressor is a key feature of ligand-dependent transcriptional repression of MLK3 by ERs. Therefore coordinated transcriptional and post-translational repression of pro-apoptotic MLK3 probably is one of the mechanisms by which ER+ breast cancer cells proliferate and survive.

Indexed as

Gene Expression Regulation, NeoplasticTranscription, GeneticBreast NeoplasmsCell Line, TumorCell Transformation, NeoplasticEstrogensFemaleHumansMAP Kinase Kinase KinasesMitogen-Activated Protein Kinase Kinase Kinase 11Models, BiologicalPromoter Regions, GeneticProtein BindingReceptors, EstrogenRepressor ProteinsResponse ElementsEstrogensMAP Kinase Kinase KinasesMitogen-Activated Protein Kinase Kinase Kinase 11Receptors, EstrogenRepressor Proteinsbreast cancerestrogen receptorestrogen response elementMLK3transcriptional regulation

Identifiers

PMID28388540
PMCPMC5464859
OpenAlexW2598118064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.